Category: R + D + i financing

The Spanish Restless Legs Syndrome Association (AESPI), in collaboration with the Spanish Sleep Society (SES), is launching the 2025 AESPI Grants call, aimed at promoting scientific research on Restless Legs Syndrome (RLS) or Willis-Ekbom Disease. Two €5.000 grants will be awarded to the best projects focused on […]

The Strategic Health Action (AES), which is managed by the Carlos III Health Institute (ISCIII) as a body under the Ministry of Science and Innovation, is the main annual tool for financing biomedical and health research in Spain. Through public funds and in calls for competitive competition, it grants economic aid for the realization […]

The Carlos III Health Institute (ISCIII) and the International Agency for Research on Cancer (IARC) are going to organize a series of online scientific seminars throughout 2022, as a starting point to promote collaboration between both entities and lay new foundations for possible new joint initiatives in the future. The ISCIII-IARC seminar series, […]

The Carlos III Health Institute (ISCIII) has presented this Tuesday to the research community the Strategic Action in Health 2022, the main funding tool for biomedical and health research in Spain, whose call announcement was published in the BOE last week . The session, which has been followed live and […]

The ISCIII has held an online information day on Thursday about Strategic Action in Health (AES) 2021, approved on December 22. The AES is the main tool for the financing of biomedical and health research in Spain, through the awarding, each year, of different grants for the development of research projects and the hiring of researchers. At the conference, this year's call was presented, and the main novelties of the AES 2021 were recalled and explained, which has an amount of 134,4 million euros, 33,2% more than in 2020.

The Council of Ministers has approved the call to launch the Precision Medicine Infrastructure associated with Science and Technology (IMPaCT) with an endowment of 25,8 million euros in grants that will allow progress in the implementation of a new form of do medicine.

The Spanish Agency for Medicines and Health Products (AEMPS), as the competent national authority for the authorization of clinical trials, proposes a series of recommendations of exceptional application during the period of the COVID-19 crisis in Spain. These measures are intended to preserve the trial activities as far as possible, guaranteeing the health care of patients, protecting their safety and well-being and preserving the traceability of the actions implemented in this health emergency situation.